US Bancorp DE Purchases 25,692 Shares of Genmab A/S Sponsored ADR $GMAB

US Bancorp DE increased its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 29.1% in the third quarter, HoldingsChannel reports. The firm owned 113,850 shares of the company’s stock after buying an additional 25,692 shares during the period. US Bancorp DE’s holdings in Genmab A/S were worth $3,492,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Orbis Allan Gray Ltd raised its stake in Genmab A/S by 38.7% in the 2nd quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock valued at $163,635,000 after acquiring an additional 2,209,659 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Genmab A/S by 152.3% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock worth $71,367,000 after buying an additional 2,084,966 shares during the period. ABC Arbitrage SA acquired a new position in Genmab A/S in the 2nd quarter valued at about $9,236,000. Federated Hermes Inc. bought a new position in Genmab A/S in the 3rd quarter valued at about $12,972,000. Finally, Cibc World Market Inc. acquired a new stake in Genmab A/S during the third quarter worth approximately $8,586,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Trading Down 6.7%

Shares of GMAB opened at $27.66 on Wednesday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. Genmab A/S Sponsored ADR has a 52-week low of $17.24 and a 52-week high of $35.43. The firm has a market cap of $17.77 billion, a price-to-earnings ratio of 17.85, a PEG ratio of 1.22 and a beta of 0.94. The business’s fifty day moving average is $31.72 and its 200-day moving average is $30.37.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. Equities analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Guggenheim lowered their target price on Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. Morgan Stanley started coverage on shares of Genmab A/S in a research report on Monday, February 16th. They set an “equal weight” rating and a $34.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Genmab A/S in a research report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price target for the company. Truist Financial reiterated a “buy” rating and issued a $48.00 price target (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Finally, HC Wainwright lifted their price objective on Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average price target of $40.58.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.